Phase I study of the VEGF/Ang-2 inhibitor BI 836880 alone or combined with the anti-programmed cell death protein-1 antibody ezabenlimab in Japanese patients with advanced solid tumors.
Noboru YamamotoTakafumi KoyamaToshio ShimizuAkiko TodakaTakeshi KawakamiDamijan ErzenAkiko SarashinaBin LiJianrui HouKentaro YamazakiPublished in: Cancer chemotherapy and pharmacology (2023)
NCT03972150, registered on June 3, 2019.